GSK opens S$130m facilities in Jurong
New plant and expanded building will step up pharmaceutical firm's output of active ingredients in its HIV medication
Singapore
PHARMACEUTICAL giant GlaxoSmithKline (GSK) unveiled a new, fully automated continuous manufacturing facility and an expanded production building at its Jurong site on Friday, worth a total of S$130 million.
The site upgrades will accelerate GSK's global supply chain and, in particular, its production of active pharmaceutical ingredients (APIs) such as Dolutegravir and Lamivudine, key assets in GSK's HIV medication.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
MAS ‘following up’ with DBS on cause of May 2 glitch in digital banking services
Nintendo to announce Switch successor details this financial year
Brokers’ take: SAC Research initiates ‘buy’ on Soilbuild with S$0.04 target
Aramco to pay US$31 billion dividend as Saudi posts budget deficit
PetroVietnam announces new oil discoveries with initial reserves of 100.5 million barrels
UBS reports first profit since taking over Credit Suisse